Gemcitabine Treatment in Pancreatic Cancer – Prognostic Factors and Outcome.
Andersson, Bodil LU
; Aho, Ursula
LU
; Pendse, Marie-Louise
; Nilsson, Johan
LU
; Tingstedt, Bobby
LU
and Andersson, Roland
LU
(2007)
In Annals of Gastroenterology
20(2).
p.130-137
- Abstract
- Background: Pancreatic cancer is generally associated with
a poor prognosis and often diagnosed in an advanced stage.
The aim of the present study was to evaluate gemcitabine
treatment concerning prognostic factors, clinical benefit, tolerance/
toxicity and survival. Methods: Patients with surgically
nonresectable, locally advanced or metastatic pancreatic
cancer treated with gemcitabine were included. Different
parameters, including clinical benefit, toxicity (WHO΄s criteria)
and survival were registered. Kaplan-Meier and Cox
regression analysis were performed. Results: Forty-two consecutive
patients were included. Median age was 62.5 ... (More) - Background: Pancreatic cancer is generally associated with
a poor prognosis and often diagnosed in an advanced stage.
The aim of the present study was to evaluate gemcitabine
treatment concerning prognostic factors, clinical benefit, tolerance/
toxicity and survival. Methods: Patients with surgically
nonresectable, locally advanced or metastatic pancreatic
cancer treated with gemcitabine were included. Different
parameters, including clinical benefit, toxicity (WHO΄s criteria)
and survival were registered. Kaplan-Meier and Cox
regression analysis were performed. Results: Forty-two consecutive
patients were included. Median age was 62.5 years,
42% were men. Gemcitabine treatment lasted in median for 5
months (0.5-29 months). Median survival from diagnosis was
9.4 months and from start of treatment 8.1 months. Thirteen
patients (32%) were alive 12 months after treatment start.
The treatment was overall well tolerated concerning toxicity.
Seven patients had transient grade 4 reactions. Of 8 parameters
selected from the univariate analysis, 3 were identified
as independent predictors for longer survival: age >60
years, ≤5 % weight loss at diagnosis and absence of metastases.
Conclusions: Gemcitabine treatment in locally advanced
and metastatic pancreatic cancer showed to be of potential
benefit and well tolerated. Age, weight loss and metastases
were independent prognostic factors for survival. The median
survival time was longer than previously reported.
Keywords: pancreatic cancer; locally advanced; gemcitabine;
treatment outcome; prognostic factors (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1141394
- author
- Andersson, Bodil
LU
; Aho, Ursula
LU
; Pendse, Marie-Louise
; Nilsson, Johan
LU
; Tingstedt, Bobby
LU
and Andersson, Roland
LU
- organization
- publishing date
- 2007
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Annals of Gastroenterology
- volume
- 20
- issue
- 2
- pages
- 130 - 137
- publisher
- Hellenic Society of Gastroenterology
- external identifiers
-
- scopus:34548526496
- ISSN
- 1108-7471
- language
- English
- LU publication?
- yes
- id
- 7bc6276e-8f2b-4bc4-9a10-293edad5ed80 (old id 1141394)
- alternative location
- http://www.annalsgastro.gr/index.php/annalsgastro/article/view/576/446
- date added to LUP
- 2016-04-01 16:58:24
- date last changed
- 2022-01-28 23:28:28
@article{7bc6276e-8f2b-4bc4-9a10-293edad5ed80,
abstract = {{Background: Pancreatic cancer is generally associated with<br/><br>
a poor prognosis and often diagnosed in an advanced stage.<br/><br>
The aim of the present study was to evaluate gemcitabine<br/><br>
treatment concerning prognostic factors, clinical benefit, tolerance/<br/><br>
toxicity and survival. Methods: Patients with surgically<br/><br>
nonresectable, locally advanced or metastatic pancreatic<br/><br>
cancer treated with gemcitabine were included. Different<br/><br>
parameters, including clinical benefit, toxicity (WHO΄s criteria)<br/><br>
and survival were registered. Kaplan-Meier and Cox<br/><br>
regression analysis were performed. Results: Forty-two consecutive<br/><br>
patients were included. Median age was 62.5 years,<br/><br>
42% were men. Gemcitabine treatment lasted in median for 5<br/><br>
months (0.5-29 months). Median survival from diagnosis was<br/><br>
9.4 months and from start of treatment 8.1 months. Thirteen<br/><br>
patients (32%) were alive 12 months after treatment start.<br/><br>
The treatment was overall well tolerated concerning toxicity.<br/><br>
Seven patients had transient grade 4 reactions. Of 8 parameters<br/><br>
selected from the univariate analysis, 3 were identified<br/><br>
as independent predictors for longer survival: age >60<br/><br>
years, ≤5 % weight loss at diagnosis and absence of metastases.<br/><br>
Conclusions: Gemcitabine treatment in locally advanced<br/><br>
and metastatic pancreatic cancer showed to be of potential<br/><br>
benefit and well tolerated. Age, weight loss and metastases<br/><br>
were independent prognostic factors for survival. The median<br/><br>
survival time was longer than previously reported.<br/><br>
Keywords: pancreatic cancer; locally advanced; gemcitabine;<br/><br>
treatment outcome; prognostic factors}},
author = {{Andersson, Bodil and Aho, Ursula and Pendse, Marie-Louise and Nilsson, Johan and Tingstedt, Bobby and Andersson, Roland}},
issn = {{1108-7471}},
language = {{eng}},
number = {{2}},
pages = {{130--137}},
publisher = {{Hellenic Society of Gastroenterology}},
series = {{Annals of Gastroenterology}},
title = {{Gemcitabine Treatment in Pancreatic Cancer – Prognostic Factors and Outcome.}},
url = {{http://www.annalsgastro.gr/index.php/annalsgastro/article/view/576/446}},
volume = {{20}},
year = {{2007}},
}